Price is choosing the drug, not the evidence.

A patient with preserved ejection fraction heart failure needs a mineralocorticoid receptor antagonist. Two agents are available. Spironolactone costs $17 to $169 a year. Finerenone costs about $9,264. Almost every one of those patients will receive spironolactone first, and finerenone only after the cheaper drug fails or proves intolerable.

Now look at what stands behind each choice. Finerenone earned its indication for this population through FINEARTS-HF, a dedicated randomized trial in 6,001 patients that met its primary endpoint. Spironolactone in the same population rests on TOPCAT, which missed its primary endpoint and showed benefit only in a post hoc regional analysis.

The standard sequence puts patients on the less firmly evidenced drug first. No guideline recommends that order. No committee voted for it. Price produced it, and it now operates as clinical policy across millions of patients.

The economics point the other way

What makes this more than an academic complaint is that the suppression is not even rational for the payer.

A 2026 economic evaluation followed 50,598 Medicare beneficiaries hospitalized with reduced ejection fraction heart failure. Mean one-year cost ran $41,802 per patient, with $25,172 of that in hospitalizations. Full four-drug therapy was projected to cut hospitalization spending by $9,780 per patient per year.

That study left its bottom line open, reporting anything from $8,556 in savings to $6,347 in added cost, because the answer depends entirely on what the drugs cost. Current pricing settles it. Negotiated Medicare prices took effect in January 2026, and generic sacubitril valsartan reached the market in July 2025. Build the regimen at those prices and it runs $2,900 to $6,200 a year. Against $9,780 in avoided hospitalization spend, that is net savings of roughly $3,600 to $6,900 per patient annually.

Plans are spending administrative dollars to slow down a therapy that pays them back.

One condition, two regimens

Before going further, a distinction that most economic analysis skips. Heart failure is not one condition. Reduced ejection fraction, roughly 40 percent or below, is the phenotype that qualifies for all four therapeutic pillars. Preserved or mildly reduced ejection fraction, roughly half of all cases, is treated with an SGLT2 inhibitor backbone plus an MRA. A beta blocker or ARNI enters only when a separate condition warrants it.

Annual cost by heart failure regimen at 2026 Medicare Part D pricing.

Regimen	Annual payer cost	Annual patient cost
Reduced EF, full four-pillar therapy	$2,900 to $6,200	$605 to $1,506
Preserved EF, SGLT2 inhibitor plus steroidal MRA	$2,160 to $2,530	$542 to $615
Preserved EF, SGLT2 inhibitor plus finerenone	$11,400 to $11,630	$2,100, at the Part D cap

The second row carries a finding worth acting on. In preserved ejection fraction heart failure on the standard pathway, the MRA costs a patient $6 to $24 a year and there is no beta blocker or ARNI at all. The SGLT2 inhibitor is nearly the entire out-of-pocket burden. Its tier placement is the highest-leverage benefit design decision available for the larger of the two phenotypes, and it is one decision rather than a program.

What prior authorization is actually doing

Prior authorization exists to steer prescribing toward a cheaper therapeutic equivalent. Across most of this regimen, no equivalent exists. An SGLT2 inhibitor has no generic substitute that produces the same outcome. The control therefore cannot redirect utilization. It can only delay or eliminate it, while shifting cost from the pharmacy line to the medical line.

The measured effect is not subtle. A 2026 analysis linked prescription orders to actual pharmacy fills across 2,183 heart failure patients, which let the authors see prescriptions that were written and never filled. Patients facing a prior authorization requirement took 6.75 times as long to fill an SGLT2 inhibitor. Median time to first fill was 31 days with the requirement and 4.6 days without. Roughly one in five never filled at all. The requirement fell more often on Black and Hispanic patients and on patients in lower-income neighborhoods.

Cost sharing finishes the job. Among 94,610 insured adults, twelve-month adherence to these therapies dropped steadily as copayments rose, and the current SGLT2 inhibitor copay of $45 to $49 a month sits squarely in the band where that decline begins. Every person in that study had coverage. Coverage did not produce use.

The window that is open right now

The Pharmacy Quality Alliance convened a technical expert panel in April 2026 to build a health plan measure for guideline-directed heart failure therapy. PQA measures feed Part D quality programs, so what gets specified this year is what plans answer for later.

That measure is the first mechanism that would make prior authorization criteria and formulary tier placement visible as quality inputs rather than as private financial decisions. Whether it does depends on two design choices being made now. The measure has to handle ejection fraction phenotype, which claims data cannot reliably carry, and it has to decide whether MRAs count at the class level or the agent level. A class-level numerator is satisfied by seventeen-dollar spironolactone, which means a plan could post excellent performance while every finerenone request sits in an authorization queue.

Those questions are cheap to answer now and expensive to revisit later.

The evidence in heart failure is not the constraint. The guidelines are not the constraint. At current Medicare pricing, even the drug prices are no longer the constraint. What stands between the evidence and the patient is a set of administrative controls built to manage substitutable spending, applied to therapies that have no substitute.

All views, analyses, and services presented here reflect my independent professional perspective, informed by more than two decades of real-world experience, and do not represent the views or positions of any current or former employer or affiliated organization.